NMN for Metabolic Optimization
One well-designed trial showed improved muscle insulin sensitivity in prediabetic women; broader metabolic benefit is unconfirmed.
Overview
Verdict
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- 250 mg/day NMN was used in the prediabetic women trial; 250-1,000 mg/day has been studied more broadly, with inconsistent metabolic results
- Expected timeframe
- 10-12 weeks
Protocol
- form
- NMN capsules or powder. Regulatory status is contested - the US FDA has determined NMN is excluded from the dietary supplement definition
- duration
- 10-12 weeks, with glucose and insulin sensitivity measured before and after
- co factor
- Take in the morning with or without food; no food-timing effect is established. Evidence is mixed. The most cited result is a randomised placebo-controlled trial of 250 mg/day NMN over 10 weeks in postmenopausal prediabetic women with overweight or obesity, which found improved muscle insulin sensitivity measured by hyperinsulinaemic-euglycaemic clamp - a rigorous method - but no change in body weight, blood pressure, liver fat, lipids or other metabolic markers. Other trials in healthy middle-aged and older adults found no meaningful metabolic changes. So one specific population showed one specific improvement, which has not been replicated or shown to extend to broader metabolic health.
- titration
- Trials have used 250, 500 and 1,000 mg/day; higher doses did not consistently produce greater metabolic effect
- starting dose
- 250 mg once daily if trialled, taken in the morning
Evidence
What the studies say
No studies are yet linked to both NMN and Metabolic Optimization.
Safety
Caveats
The single positive metabolic finding came from one small trial in postmenopausal prediabetic women and used a research-grade clamp measurement that consumer testing cannot replicate - do not assume it generalises. For metabolic health, weight loss, resistance and aerobic exercise, dietary change, metformin and GLP-1 receptor agonists have far stronger evidence, and prediabetes responds well to structured lifestyle programmes. If you have metabolic concerns, get HbA1c, lipids, liver function and blood pressure measured. Regulatory note: NMN has been determined by the US FDA to be excluded from the dietary supplement definition; availability varies by country. Safety: human trials up to 1,000 mg/day over 6-12 weeks report good tolerability, with occasional nausea, diarrhoea, headache and flushing. There is no established upper intake level and no long-term human safety data. NAD+ supports cell proliferation and preclinical work raises the possibility of supporting tumour growth - discuss with your oncologist if you have a cancer history. Interactions are poorly characterised, including with diabetes medication where any additional glucose effect would matter. Avoid in pregnancy and breastfeeding.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.